$CRMD

CorMedix (CRMD) reported Q2 revenue of $101.9M, up from $39.7M a year ago, with net income of $26M. Management raised adjusted EBITDA guidance but kept full-year revenue guidance unchanged. DefenCath and the Melinta portfolio drove growth, with new supply agreements signed. The company expects to submit an sNDA for REZZAYO in Q3. Operating expenses increased due to Melinta's costs and R&D spending. Hedge fund ownership rose, while short interest remained high at 22.30%.

CorMedix (CRMD) was upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, which often impacts stock prices. The Zacks rating system tracks consensus EPS estimates, and upgrades typically signal a positive earnings outlook, potentially boosting the stock price.

CorMedix (CRMD) reported Q2 2026 revenue of $101.9M and adjusted EBITDA of $58.7M. The company signed a commercial supply agreement for DefenCath with a large dialysis organization, covering all top U.S. providers. Full-year revenue guidance was reaffirmed at $325M-$345M, while adjusted EBITDA guidance was raised to $125M-$140M. CorMedix anticipates submitting an sNDA for REZZAYO in Q3 2026, with potential FDA action in H1 2027. The company plans to invest in commercial infrastructure for a pote

CorMedix reported Q2 2026 progress on DefenCath and its REZZAYO pipeline. The company secured a multi-year supply agreement covering all leading U.S. dialysis providers, maintained DefenCath utilization through the TDAPA transition, and raised 2026 adjusted EBITDA guidance to $125-$140 million. It plans a REZZAYO prophylaxis sNDA submission in Q3 2026, with FDA action expected in H1 2027.

U.S. stock futures paused after the S&P 500 hit a record close, with softer July PPI easing near-term Fed rate-hike fears. Retail sales are set for Friday. Capricor (CAPR) surged after Cantor Fitzgerald upgraded it to Overweight and raised its target to $28. Other movers include AMAT, SNDK, WDAY, CRM, and SPCX.

CorMedix Inc. shares rose 17% after Q2 2026 results. The company reported revenue of $101.9M, nearly tripling from $39.7M a year earlier, and raised full-year adjusted EBITDA guidance to $125M to $140M. DefenCath revenue was $66.1M. CorMedix plans a Q3 2026 FDA filing for Rezzayo sNDA.

CorMedix Therapeutics (Nasdaq: CRMD) reported Q2 2026 consolidated revenue of $101.9M, including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M and adjusted EBITDA $58.7M. The company maintained FY2026 revenue guidance at $325M-$345M and raised adjusted EBITDA to $125M-$140M, with a REZZAYO sNDA FDA submission expected in Q3 2026.

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CORMEDIX THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Rais

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. crmd-20260623 FALSE 0001410098 0001410098 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

CorMedix (CRMD) shares surged over 18% after the company reported strong first-quarter results, with revenue reaching $127.4 million, significantly exceeding Wall Street's expectations. The impressive growth was largely driven by DefenCath sales, prompting CorMedix to raise its full-year 2026 revenue and adjusted EBITDA guidance. Retail sentiment on Stocktwits also shifted to bullish following the positive news.